Cognition Therapeutics Inc
NASDAQ:CGTX
Cognition Therapeutics Inc
NASDAQ:CGTX
Price:
1.96 USD
1.03%
Market Closed
Updated:
May 20, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of CGTX.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CGTX
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
CGTX Competitors Multiples
Cognition Therapeutics Inc Competitors
Cognition Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Cognition Therapeutics Inc
NASDAQ:CGTX
|
78.5m USD | 0 | -3 | -1 | -1 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
731.8B USD | 20.4 | 119.2 | 58.4 | 66.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 16.5 | 45.1 | 33.6 | 36.9 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
372.2B USD | 4.3 | 9.7 | 11.9 | 15.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
332.3B USD | 5.4 | 144.1 | 35.9 | 58.5 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
187.7B GBP | 5 | 37.6 | 174.5 | 278.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
189B CHF | 3.2 | 16.4 | 9.3 | 11 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182.7B CHF | 3.4 | 11.5 | 8.7 | 12.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
162.3B USD | 2.9 | -525.3 | 12.7 | 20.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
